Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million
Lachen, Switzerland, March 1st, 2018: Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017, with sales of €1.72 billion...
Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A
Lachen, Switzerland, January 22nd, 2018: Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia. The study...